Abstract:Deciphering information hidden in the gene expression assays for identifying disease subtypes has significant importance in precision medicine. However, computational limitations thwart this process due to the intricacy of the biological networks and the curse of dimensionality of gene expression data. Therefore, clustering in such scenarios often becomes the first choice of exploratory data analysis to identify natural structures and intrinsic patterns in the data. However, sparse and high dimensional nature of omics data prevents conventional clustering algorithms to discover subtypes that are clinically relevant and statistically significant. Hence, non-linear dimensionality reduction coupled with clustering in such scenarios often becomes imperative to improve the clustering results. In this study, we present a robust pipeline to discover disease subtypes with clinical relevance. Specifically, we focus on discovering patient sub-groups that have a residual life patterns remarkably different from other sub-groups. This is significant because by refining prognosis, subtyping can reduce uncertainty in approximating patients expected outcome. The methodology present is based on robust correlation estimation , UMAP – a non-linear dimensionality reduction method and mapper – a tool from topology. Notably, we suggest a method for improving the robustness of the correlation matrix of gene expression data for improving the clustering results. The performance of the model is evaluated by applying to five cancer datasets obtained through TCGA and comparisons are performed with some state of the art methods of NEMO, RSC-OTRI and SNF with regard to log−rank test and Restricted Life Expectancy Difference . For example in GBM dataset, the minimum separation for any two discovered subtypes is 221 days which is significantly higher than the other methodologies. We also compared the results without using the robust correlation based estimate and observed that robust correlation improves separability between survival curves significantly. From the results we infer that our methodology performs better compared to other methodologies with regard to separating survival curves of patient sub-groups despite using single omics profiles of patients compared to multiple omics profiles of SNF and NEMO. Pathway over-representation analysis is performed on the final clustering results to investigate the biological underpinnings characterising each subtype.

Correlated Mixed Membership Modeling of Somatic Mutations

A Dirichlet-multinomial mixed model for determining differential abundance of mutational signatures

A latent variable model for evaluating mutual exclusivity and co-occurrence between driver mutations in cancer

Bayesian modeling of mutual exclusivity in cancer mutations

Identifying somatic fingerprints of cancers defined by germline and environmental risk factors

A Pan-Cancer and Polygenic Bayesian Hierarchical Model for the Effect of Somatic Mutations on Survival

Hierarchical Bayesian analysis of somatic mutation data in cancer

Topical hidden genome: discovering latent cancer mutational topics using a Bayesian multilevel context-learning approach

Improving personalized prediction of cancer prognoses with clonal evolution models

Network-Based Coverage of Mutational Profiles Reveals Cancer Genes

A new correlation clustering method for cancer mutation analysis

Predictive Modeling of Novel Somatic Mutation Impacts on Cancer Prognosis: A Machine Learning Approach Using the COSMIC Database

Mutation-Profile-Based Methods for Understanding Selection Forces in Cancer Somatic Mutations: A Comparative Analysis

Cancer classification and pathway discovery using non-negative matrix factorization

Analyzing Tumor Heterogeneity by Incorporating Long-Range Mutational Influences and Multiple Sample Data into Heterogeneity Factorial Hidden Markov Model

Robust correlation estimation and UMAP assisted topological analysis of omics data for disease subtyping

An Expanded Association Approach for Rare Germline Variants with Copy-Number Alternation.

Using somatic mutation data to test tumors for clonal relatedness

Inching Towards Precision Medicine For Multiple Myeloma With Causal Network Models.

Integrating Somatic Mutations for Breast Cancer Survival Prediction Using Machine Learning Methods

Robust discovery of mutational signatures using power posteriors